mdl 100240 has been researched along with Body Weight in 2 studies
*Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agabiti-Rosei, E; Bova, S; Cavallin, M; Mazzocchi, G; Nussdorfer, GG; Pessina, AC; Rizzoni, D; Rossi, GP | 1 |
| Agabiti-Rosei, E; Bova, S; Neri, G; Nussdorfer, GG; Pessina, AC; Rizzoni, D; Rossi, GP; Sacchetto, A | 1 |
2 other study(ies) available for mdl 100240 and Body Weight
| Article | Year |
|---|---|
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.
Topics: Adrenomedullin; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Benzazepines; Biomarkers; Blood Pressure; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Heart; Hypertension; Male; Models, Cardiovascular; Neprilysin; Organ Size; Peptides; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Receptor, Bradykinin B2; Receptors, Bradykinin; Severity of Illness Index; Systole; Treatment Outcome; Vasoconstrictor Agents | 2002 |
Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Aorta; Benzazepines; Blood Pressure; Body Weight; Cardiovascular Diseases; Hypertension; In Vitro Techniques; Male; Neprilysin; Organ Size; Pyridines; Ramipril; Rats; Vasoconstriction | 2002 |